Business Wire

Aircall unveils Aircall Workspace, a dynamic and intelligent hub for customer communication and agent collaboration

Share

Scott Chancellor, CEO, delivers the keynote address at the company’s 10th anniversary Town Hall to showcase the benefits of Aircall Workspace for new and prospective customers

There are many milestones for Aircall to celebrate as it reaches its first decade, namely 19,000 customers, 1,500 partners, and 600 global employees. Yet the big news is future-facing, as the company announces Aircall Workspace, positioning the platform for another decade of growth.

Aircall Workspace builds on the strengths of the existing platform and introduces a revamped user experience. The new hub integrates conversations across all channels (including voice and text) and provides customer and conversation intelligence, agent collaboration, insights, and task automation (e.g., tagging, CRM insights). Aircall Workspace eliminates the common challenges of disjointed customer interactions by ensuring that agents have access to information and capabilities exactly when and where needed to drive business efficiency and efficacy.

Additionally, Aircall Workspace provides users access to Aircall’s robust and growing suite of AI-driven capabilities, including call summaries, sentiment analysis and key topic tagging, which are now available at their fingertips to add even more context to conversations.

Luxury Swiss watchmaker, Breitling, a valued Aircall customer, has moved fast to adopt Aircall’s AI. Kristof Desmedt, Global Contact Center Manager at Brietling, comments: “Everybody says it in every industry and so on, but it, [AI], does help us to get stuff done faster. Somebody might not have the time to listen to a five-minute call. But if an AI call summary helps us to draft an email and move to action quicker, well, eventually, the client will be happier as well. AI has tremendous potential to help our agents help our clients better in the first place.”

Starting today, Aircall Workspace will begin open beta. It delivers greater collaboration, control and confidence:

  • Agents can interact with customers across different channels, yet retain a single view of all conversations.
  • Staying organized around conversations becomes seamless with a larger, more intuitive, and re-sizeable workspace layout.
  • Teams can communicate and problem-solve together with real-time collaboration, internal notes and activity cues.
  • AI and Analytics provide agents with all the historical context, predictive intelligence and task automation they need to drive better customer experiences.

CPO Tom Chen, commented: “We can’t wait for our customers to try Aircall Workspace. It will simplify what is often extremely complex, balancing all the different customer touchpoints with the right mixture of human judgment and AI. Users can also customize the platform to fit their needs, an important feature that demonstrates our commitment to continuous improvement and innovation.”

Aircall Workspace will be demonstrated at the company’s global Town Hall on 10/10 to mark its 10th anniversary, streaming to invited customers and partners in New York, London, Paris, Sydney and San Francisco.

Marking this milestone launch, Scott Chancellor, CEO, explains: “To succeed in today’s constantly evolving competitive landscape, businesses must foster meaningful connections with their customers, combining the power of human and AI-driven insight to unlock value from every interaction. At Aircall, we are dedicated to making that process seamless, and Aircall Workspace is how we start.”

About Aircall

Aircall is the communication and intelligence platform that empowers Sales and Customer Support teams to connect, communicate, and grow. More than 19,000 customers around the world use Aircall to interact with customers. The platform integrates seamlessly with all major CRM and Help Desk solutions, is easy-to-use and provides the insights companies need to make data-informed decisions about team staffing, performance, business growth and more.

Aircall has expanded its international footprint and currently has over 700 employees from 40 nationalities spread over 7 offices – New York, San Francisco, Paris, London, Sydney, Berlin and Madrid – and was named one of Built In’s Best Places to Work. As part of the Deloitte Fast 500 list, Aircall achieved Centaur status after securing over $100 million in annual recurring revenue in 2022.

https://aircall.io/

View source version on businesswire.com: https://www.businesswire.com/news/home/20241009295510/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release

Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release

Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release

Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye